Currently, BioNTech SE ADR [BNTX] is trading at $115.98, down -2.10%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The BNTX shares have gain 9.34% over the last week, with a monthly amount glided 25.83%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
BioNTech SE ADR [NASDAQ: BNTX] stock has seen the most recent analyst activity on January 16, 2026, when Goldman upgraded its rating to a Buy but kept the price target unchanged to $142 for it. Previously, H.C. Wainwright reaffirmed its Buy rating on June 05, 2025, and elevated its price target to $145. On May 29, 2025, Goldman initiated with a Neutral rating and assigned a price target of $110 on the stock. Citigroup started tracking the stock assigning a Buy rating and suggested a price target of $145 on March 13, 2025. Truist initiated its recommendation with a Buy and recommended $172 as its price target on January 10, 2025. Wells Fargo started tracking with a Overweight rating for this stock on December 11, 2024, and assigned it a price target of $170. In a note dated December 02, 2024, BMO Capital Markets reiterated an Outperform rating on this stock.
This stock has fluctuated between a low of $81.20 and a high of $126.77 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $144.2 within the next 12 months. BioNTech SE ADR [NASDAQ: BNTX] shares were valued at $115.98 at the most recent close of the market. An investor can expect a potential return of 24.33% based on the average BNTX price forecast.
Analyzing the BNTX fundamentals
Trailing Twelve Months sales for BioNTech SE ADR [NASDAQ:BNTX] were 3.53B which represents 29.80% growth. Gross Profit Margin for this corporation currently stands at 0.82% with Operating Profit Margin at -0.3%, Pretax Profit Margin comes in at -0.17%, and Net Profit Margin reading is -0.18%. To continue investigating profitability, this company’s Return on Assets is posted at -0.03, Equity is -0.03 and Total Capital is -0.05. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for BioNTech SE ADR [NASDAQ:BNTX] is 7.12. As well, the Quick Ratio is 7.02, while the Cash Ratio is 4.54. Considering the valuation of this stock, the price to sales ratio is 7.89, the price to book ratio is 1.28.
Transactions by insiders
Recent insider trading involved Tureci Ozlem, Officer, that happened on Nov 28 ’25 when 0.12 million shares were purchased. Officer, Medine GmbH completed a deal on Nov 13 ’25 to buy 1.11 million shares. Meanwhile, Director Jeggle Helmut Wolfgang bought 0.15 million shares on Nov 05 ’25.
